Vildagliptin-d6

Vildagliptin-d6 (LAF237-d6) is deuterium labeled Vildagliptin. Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity[1].

Product Specifications

Product Name Alternative

LAF237-d6 ; NVP-LAF 237-d6

UNSPSC

12352005

Target

Apoptosis; Dipeptidyl Peptidase; Ferroptosis; Isotope-Labeled Compounds

Related Pathways

Apoptosis; Metabolic Enzyme/Protease; Others

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease; Cancer

Smiles

O=C(N1[C@@H](C([2H])([2H])C([2H])([2H])C1([2H])[2H])C#N)CNC23CC4(CC(CC(C4)C3)C2)O

Molecular Formula

C17H19D6N3O2

Molecular Weight

309.44

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Wu YJ, et al. Dipeptidyl peptidase-4 inhibitor, vildagliptin, inhibits pancreatic beta cell apoptosis in associationwith its effects suppressing endoplasmic reticulum stress in db/db mice. Metabolism. 2015 Feb;64 (2) :226-35.|[3]Villhauer EB, et al. 1-[[ (3-hydroxy-1-adamantyl) amino]acetyl]-2-cyano- (S) -pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem. 2003 Jun 19;46 (13) :2774-89.